C08F22/10

PROCESS FOR CONVERTING A POLYMERIC ESTER TO A POLYMERIC ACID
20200190230 · 2020-06-18 ·

The present invention generally relates to processes for converting an ester group to an acid group for polymers having a pendant ester of an acid group. This process is generally performed using an aqueous strong base.

PROCESS FOR CONVERTING A POLYMERIC ESTER TO A POLYMERIC ACID
20200190230 · 2020-06-18 ·

The present invention generally relates to processes for converting an ester group to an acid group for polymers having a pendant ester of an acid group. This process is generally performed using an aqueous strong base.

PATTERN FORMING METHOD
20200166836 · 2020-05-28 ·

A pattern forming method comprises dispensing a curable composition onto an underlayer of a substrate; bringing the curable composition into contact with a mold; irradiating the curable composition with light to form a cured film; and separating the cured film from the mold. The proportion of the number of carbon atoms relative to the total number of atoms in the underlayer is 80% or more. The dispensing step comprises a first dispensing step of dispensing a curable composition (A1) substantially free of a fluorosurfactant onto the underlayer, and a second dispensing step of dripping a droplet of a curable composition (A2) having a fluorosurfactant concentration in components excluding a solvent of 1.1% by mass or less onto the curable composition (A1) discretely.

TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE
20200140448 · 2020-05-07 ·

A temozolomide compound according to formula (I)

##STR00001##

is described, wherein R.sup.1, L.sup.1, and X are defined herein. The temozolomide compound can be used to prepare polymers comprising temozolomide. Additionally, the polymers comprising temozolomide can be particularly useful in the treatment of certain diseases.

TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE
20200140448 · 2020-05-07 ·

A temozolomide compound according to formula (I)

##STR00001##

is described, wherein R.sup.1, L.sup.1, and X are defined herein. The temozolomide compound can be used to prepare polymers comprising temozolomide. Additionally, the polymers comprising temozolomide can be particularly useful in the treatment of certain diseases.

Polymers containing a 1,1-disubstituted alkene compound

Disclosed is a block copolymer having a first polymer block including a first primary monomer that is a 1,1-disubstituted alkene compound, wherein the first primary monomer is present at a concentration of about 50 weight percent or more, based on the total weight of the first polymer block, the first polymer block covalently bonded to a second polymer block including a second primary monomer different from the first primary monomer, wherein the second primary monomer is present at a concentration of about 50 weight percent or more, based on the total weight of the second polymer block. Also disclosed is a polymer comprising at least one monomer of a 1,1-disubstituted alkene compound having a weight average molecular weight of about 3000 daltons or more, wherein the polymer is substantially free of a melting temperature and is substantially free of a glass transition temperature of about 15 C. or more.

Polymers containing a 1,1-disubstituted alkene compound

Disclosed is a block copolymer having a first polymer block including a first primary monomer that is a 1,1-disubstituted alkene compound, wherein the first primary monomer is present at a concentration of about 50 weight percent or more, based on the total weight of the first polymer block, the first polymer block covalently bonded to a second polymer block including a second primary monomer different from the first primary monomer, wherein the second primary monomer is present at a concentration of about 50 weight percent or more, based on the total weight of the second polymer block. Also disclosed is a polymer comprising at least one monomer of a 1,1-disubstituted alkene compound having a weight average molecular weight of about 3000 daltons or more, wherein the polymer is substantially free of a melting temperature and is substantially free of a glass transition temperature of about 15 C. or more.

Methods of making voxelated liquid crystal elastomers

A method of making a shape-programmable liquid crystal elastomer. The method includes preparing an alignment cell having a surface programmed with a plurality of domains. A cavity of the alignment cell is filled with a monomer solution. The monomers of the monomer solution are configured to align to the surface of the alignment cell. The aligned monomers are polymerized by Michael Addition. The polymerized monomers are then cross-linked to form a cross-linked liquid crystal elastomer. The cross-linking traps monomer alignment into a plurality of voxels with each voxel having a director orientation.

Methods of making voxelated liquid crystal elastomers

A method of making a shape-programmable liquid crystal elastomer. The method includes preparing an alignment cell having a surface programmed with a plurality of domains. A cavity of the alignment cell is filled with a monomer solution. The monomers of the monomer solution are configured to align to the surface of the alignment cell. The aligned monomers are polymerized by Michael Addition. The polymerized monomers are then cross-linked to form a cross-linked liquid crystal elastomer. The cross-linking traps monomer alignment into a plurality of voxels with each voxel having a director orientation.

OLIGOMER AND LITHIUM BATTERY

A oligomer and a lithium battery are provided. The oligomer is obtained by a polymerization reaction of a compound containing at least one ethylenically unsaturated group and a nucleophile compound. The compound containing at least one ethylenically unsaturated group is selected from a group consisting of a maleimide-based compound, an acrylate ester-based compound, a methacrylate ester-based compound, an acrylamide-based compound, a vinylamide-based compound and a combination thereof. The nucleophile compound is selected from a group consisting of monomaleimide, trithiocyanuric acid, hydantoin, hydantoin derivative, thiohydantoin, thiohydantoin derivative and a combination thereof.